Bluebird bio Inc represents values of innovation, integrity, and patient-centricity. The company is driven by a corporate philosophy that centers around transforming the lives of patients with severe diseases through the development of potentially curative gene therapies. With a focus on revolutionizing the approach to treating genetic diseases, bluebird bio Inc is committed to harnessing the power of gene therapy and gene editing technologies to provide long-term and durable solutions for patients in need. By prioritizing scientific excellence and collaboration, bluebird bio Inc strives to advance the field of gene therapy and improve outcomes for patients worldwide.

Bluebird bio Inc is primarily present in the United States, with its headquarters located in Cambridge, Massachusetts. As a leading biotechnology company, bluebird bio Inc focuses on developing gene therapies for severe genetic diseases and cancer. It operates across various states in the US and has a significant presence in the biotech hubs of California and North Carolina. While its primary presence is in the US, bluebird bio Inc also has a global presence through collaborations and partnerships with international research institutions and pharmaceutical companies.

Some significant milestones achieved by Bluebird Bio Inc include the approval and commercialization of their groundbreaking gene therapy, ZYNTeglo, for the treatment of transfusion-dependent β-thalassemia. The company also received regulatory approval for their gene therapy product, Skysona, for the treatment of cerebral adrenoleukodystrophy. Bluebird Bio has successfully advanced its portfolio of gene and cell therapies for various genetic diseases, pushing the boundaries of treatment options available for patients. Additionally, the company collaborated with Bristol Myers Squibb to develop and commercialize novel cancer therapies, aimed at further advancing personalized medicine.

Bluebird bio Inc is a renowned biotechnology company specializing in gene therapy. Founded in 1992, it has its headquarters in Cambridge, Massachusetts. The company is dedicated to developing potentially transformative gene therapies for severe genetic and rare diseases. Bluebird bio Inc's cutting-edge research and innovation aim to improve patients' lives by addressing the underlying causes of their diseases. With a strong focus on cell and gene therapies, they leverage their expertise to create groundbreaking treatments. Bluebird bio Inc has established collaborations with leading healthcare organizations, further advancing their pioneering work in the field of gene therapy.

The main competitors of bluebird bio Inc in the market include CRISPR Therapeutics, Editas Medicine, Sangamo Therapeutics, and Intellia Therapeutics.

Bluebird bio Inc is primarily active in the biotechnology industry.

The business model of bluebird bio Inc is focused on developing and commercializing transformative gene therapies for severe genetic diseases and cancer. Through its innovative gene editing and delivery technologies, bluebird bio aims to provide potentially curative treatments for patients with limited or no treatment options. The company's approach involves genetically modifying a patient's own cells to produce functional proteins, correct genetic mutations, or enhance the immune system to target and eliminate cancer cells. With a goal of improving patients' lives, bluebird bio works towards advancing gene therapy research and expanding its portfolio to address various genetic diseases and conditions.

Det bluebird bio P/E-forhold er -0,19.

bluebird bio KUV er 0,58.

AlleAktien Kvalitetsscore for bluebird bio er 4/10.

Den forventede bluebird bio omsætning er 88,24 mio. USD.

Den forventede bluebird bio indtjening er -271,35 mio. USD.

The company bluebird bio Inc. is a biotechnology company based in Massachusetts, USA. It was founded in 1992 and specializes in the research, development, and commercialization of therapies for serious diseases. The company focuses on gene therapies and stem cell therapies for diseases that traditional medications cannot sufficiently treat. The company currently has three major divisions: Oncology, Rare Diseases, and Cancer Immunotherapy. In the oncology division, bluebird bio is researching and developing gene therapies for the treatment of leukemia and myeloma. The company has already received approvals for its therapy for beta-thalassemia and is actively developing gene therapies for other diseases such as sickle cell anemia. In the rare diseases field, the company is also developing gene therapies for inherited diseases. One of its key therapies in this area is the LentiGlobin beta-thalassemia therapy. The cancer immunotherapy division is dedicated to developing therapies that utilize the immune system to fight cancer. The company offers a range of products, including gene therapies, stem cell therapies, and cell therapies. One of these is the Lenti-D therapy, used for the treatment of orphan diseases like childhood leukodystrophy (MLD). Another important therapy is the LentiGlobin beta-thalassemia therapy for the treatment of beta-thalassemia. The company has also developed a cell therapy called BB2121, used for multiple myeloma. The business model of bluebird bio is based on developing innovative therapies to cure serious diseases that traditional medications cannot reach. The company works closely with regulatory authorities in the US and Europe to effectively and quickly market its therapies once they are approved. In the past, the company has formed partnerships with other biotechnology and pharmaceutical companies to advance its research and development. There are numerous ongoing clinical research projects that the company is currently conducting to bring new therapies to the market. Overall, bluebird bio has strong venture capital and investor support. In December 2016, the company announced a partnership with Celgene, one of the largest biotech companies in the world, to jointly develop therapies for treating cancer. In conclusion, bluebird bio is a biotechnology company that specializes in researching and developing gene therapies, stem cell therapies, and cell therapies to treat serious diseases that traditional medications cannot reach. It offers a range of products and actively works on developing therapies that utilize the immune system to effectively fight cancer. The company collaborates closely with regulatory authorities and other companies to conduct its research and development and bring new therapies to the market.

bluebird bio udbetaler et udbytte på 0 USD fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for bluebird bio, eller selskabet udbetaler ikke udbytte.

ISIN'en for bluebird bio er US09609G1004.

WKN for bluebird bio er A1W025.

Tickeren for bluebird bio er BLUE.

I løbet af de sidste 12 måneder betalte bluebird bio en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil bluebird bio sandsynligvis betale en dividende på 0 USD.

Udbytteafkastet for bluebird bio er i øjeblikket .

bluebird bio betaler kvartalsvis udbytte. Dette uddeles i månederne .

bluebird bio betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 USD. Dette svarer til et dividendeafkast på 0 %.

bluebird bio bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på bluebird bio fra den 5.11.2024 på 0 USD, skulle du have haft aktien i din portefølje før ex-datoen den 5.11.2024.

Udbetalingen af det sidste udbytte blev foretaget den 5.11.2024.

I løbet af 2023 udbetalte bluebird bio 0 USD i form af dividender.

Udbytterne fra bluebird bio udbetales i USD.